Are the epigenetic changes predictive of therapeutic efficacy
for psychiatric disorders? A translational approach towards
novel drug targets

J 2023

Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets

MICALE, Vincenzo, Di Bartolomeo MARTINA, Di Martino SERENA, Tibor ŠTARK, Bernardo DELL'OSSO et. al.

Basic information

Original name

Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets

Authors

MICALE, Vincenzo (guarantor), Di Bartolomeo MARTINA, Di Martino SERENA, Tibor ŠTARK (703 Slovakia, belonging to the institution), Bernardo DELL'OSSO, Filippo DRAGO and Claudio ADDARIO

Edition

PHARMACOLOGY & THERAPEUTICS, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2023, 0163-7258

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 13.500 in 2022

RIV identification code

RIV/00216224:14110/23:00130255

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.pharmthera.2022.108279

UT WoS

000906912700004

Keywords in English

Schizophrenia; Bipolar disorder; Depression; DNA methylation; Epigenetics; Antidepressants; Antipsychotics

Abstract

V originále

The etiopathogenesis of mental disorders is not fully understood and accumulating evidence support that clinical symptomatology cannot be assigned to a single gene mutation, but it involves several genetic factors. More specifically, a tight association between genes and environmental risk factors, which could be mediated by epigenetic mechanisms, may play a role in the development of mental disorders. Several data suggest that epigenetic modifications such as DNA methylation, post-translational histone modification and interference of microRNA (miRNA) or long non-coding RNA (lncRNA) may modify the severity of the disease and the outcome of the therapy. Indeed, the study of these mechanisms may help to identify patients particularly vulnerable to mental disorders and may have potential utility as biomarkers to facilitate diagnosis and treatment of psychiatric disorders. This article summarizes the most relevant preclinical and human data showing how epigenetic modifications can be central to the therapeutic efficacy of antidepressant and/or antipsychotic agents, as possible predictor of drugs response.

Citovat

MICALE, Vincenzo, Di Bartolomeo MARTINA, Di Martino SERENA, Tibor ŠTARK, Bernardo DELL'OSSO, Filippo DRAGO and Claudio ADDARIO. Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets. PHARMACOLOGY & THERAPEUTICS. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2023, vol. 241, January 2023, p. 1-39. ISSN 0163-7258. Available from: https://dx.doi.org/10.1016/j.pharmthera.2022.108279.

@article{2251385,
   author = {Micale, Vincenzo and Martina, Di Bartolomeo and Serena, Di Martino and Štark, Tibor and Dell'Osso, Bernardo and Drago, Filippo and Addario, Claudio},
   article_location = {OXFORD},
   article_number = {January 2023},
   doi = {http://dx.doi.org/10.1016/j.pharmthera.2022.108279},
   keywords = {Schizophrenia; Bipolar disorder; Depression; DNA methylation; Epigenetics; Antidepressants; Antipsychotics},
   language = {eng},
   issn = {0163-7258},
   journal = {PHARMACOLOGY & THERAPEUTICS},
   title = {Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets},
   url = {https://www.sciencedirect.com/science/article/pii/S0163725822001735?via%3Dihub},
   volume = {241},
   year = {2023}
}

TY  - JOUR
ID  - 2251385
AU  - Micale, Vincenzo - Martina, Di Bartolomeo - Serena, Di Martino - Štark, Tibor - Dell'Osso, Bernardo - Drago, Filippo - Addario, Claudio
PY  - 2023
TI  - Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets
JF  - PHARMACOLOGY & THERAPEUTICS
VL  - 241
IS  - January 2023
SP  - 1-39
EP  - 1-39
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 01637258
KW  - Schizophrenia
KW  - Bipolar disorder
KW  - Depression
KW  - DNA methylation
KW  - Epigenetics
KW  - Antidepressants
KW  - Antipsychotics
UR  - https://www.sciencedirect.com/science/article/pii/S0163725822001735?via%3Dihub
N2  - The etiopathogenesis of mental disorders is not fully understood and accumulating evidence support that clinical symptomatology cannot be assigned to a single gene mutation, but it involves several genetic factors. More specifically, a tight association between genes and environmental risk factors, which could be mediated by epigenetic mechanisms, may play a role in the development of mental disorders. Several data suggest that epigenetic modifications such as DNA methylation, post-translational histone modification and interference of microRNA (miRNA) or long non-coding RNA (lncRNA) may modify the severity of the disease and the outcome of the therapy. Indeed, the study of these mechanisms may help to identify patients particularly vulnerable to mental disorders and may have potential utility as biomarkers to facilitate diagnosis and treatment of psychiatric disorders. This article summarizes the most relevant preclinical and human data showing how epigenetic modifications can be central to the therapeutic efficacy of antidepressant and/or antipsychotic agents, as possible predictor of drugs response.
ER  -

MICALE, Vincenzo, Di Bartolomeo MARTINA, Di Martino SERENA, Tibor ŠTARK, Bernardo DELL'OSSO, Filippo DRAGO and Claudio ADDARIO. Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets. \textit{PHARMACOLOGY \&{} THERAPEUTICS}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2023, vol.~241, January 2023, p.~1-39. ISSN~0163-7258. Available from: https://dx.doi.org/10.1016/j.pharmthera.2022.108279.

Detailed Information on Publication Record